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Abstract 
 
CATHERINE ANNE CRIDDLE: A Comparison of Mitragyna Speciosa and Mitragynine 
against Opioids on Thermal Nociception in Rats 
(Under the direction of Kenneth Sufka) 
 
The purpose of this experiment is to compare Mitragyna speciosa (M. speciosa) and its 
active component, mitragynine, a known µ-opioid receptor (MOR) agonist, against well-
known and commonly abused opioids, morphine and oxycodone. Another goal of this 
research is to determine if these compounds are also active when administered orally as is 
typical in human users. Male Sprague-Dawley rats were administered M. speciosa and 
mitragynine both intraperitoneally (IP) and orally and their antinociceptive effects were 
evaluated on the hotplate. Mitragynine exhibited antinociceptive effects similar to 
oxycodone when administered both IP and orally. M. speciosa exhibited a trend towards 
antinociceptive effects when administered both IP and orally. This research demonstrates 
that M. speciosa possesses properties like oxycodone and raises the possibility of an 
abuse liability which might warrant consideration for restrictions on the consumer 
marketplace.
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Introduction 
 
 Many botanical products are easily accessible to consumers and are used 
recreationally as well as to remedy an assortment of medical conditions (Dennehy, 
Tsourounis & Miller, 2005). Unlike therapeutically used botanicals, botanicals used 
recreationally are typically under-researched (Humberston, Akhtar & Krenzelok, 2003; 
Teschke, Schwarzenboeck & Akinci, 2008). Often under-researched botanicals contain a 
myriad of components with dangerous properties such as toxicity or the potential for 
abuse. The importance of uncovering these dangerous properties cannot be over stressed 
(Humberston et al., 2003; Teschke et al., 2008). Because of the concerns outlined above, 
the need for a more systematic look at models that can quantify abuse liability is crucial. 
Our approach to this problem is discussed below using the botanical product, Mitragyna 
speciosa (M. speciosa). 
 M. speciosa, a plant native to Thailand and Southeast Asia, has traditionally been 
used by rural laborers in those areas as a mild narcotic in place of opium (Burkill, 1966; 
Leon et al., 2009). Like opium, M. speciosa alleviated workers’ pain caused by manual 
labor and increased endurance by preventing fatigue (Assanangkornchai, Muekthong, 
Sam-Angsri & Pattanasattayawong, 2007; Jansen & Prast, 1988a, 1988b; Pichainarong, 
Chaveepojnkamjorn, Khobjit, Veerachai & Sujirarat, 2004; Suwanlert, 1975). Also 
known as kratom, krathom, ketum and biak-biak, the leaves of this plant can be smoked, 
chewed, or dried and steeped to make tea (Burkill, 1966; Jansen & Prast, 1988a; 
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Suwanlert, 1975). M. speciosa has also been used in bandages for wounds and served as a 
remedy for fever, diarrhea, and cough (Burkill & Haniff, 1930). Today, it is used in 
Southeast Asia primarily for recreational purposes, for pain management, and for 
treatment of withdrawal symptoms of opiate addiction (Assanangkornchai et al., 2007; 
Jansen & Prast, 1988a, 1988b; Suwanlert, 1975; Vicknasingam, Narayanan, Beng & 
Mansor, 2010).  
 The ingestion of M. speciosa produces a stimulant effect at low dosages and an 
opioid-like effect at medium to high dosages. This dose-dependent effect has been 
reported by consumers and exhibited in animal models (Assanangkornchai et al., 2007; 
Grewal, 1932; Jansen & Prast, 1988a, 1988b; Macko, Weisbach & Douglas, 1972; 
Pichainarong et al., 2004; Suwanlert, 1975; Watanabe, Yano, Horie & Yamamoto, 1997; 
Yamamoto et al., 1999). In low to medium doses, some individuals regard the effects of 
M. speciosa as unpleasant, experiencing anxiety and agitation (“Kratom Dosage,” 2015; 
Siebert, 2006; “Kratom Addiction,” n.d.). Similarly, in high doses, whether the effects of 
M. speciosa are euphoric or dysphoric is highly dependent on the individual. Some 
individuals experience nausea, sedation, constipation, and itching after consuming high 
doses of M. speciosa (Assanangkornchai et al., 2007; Jansen & Prast, 1988a, 1988b; 
Suwanlert, 1975).  
 Mitragynine, an indole alkaloid and the primary active component of M. speciosa, 
is responsible for the opioid-like activity of the plant (Adkins, Boyer & McCurdy, 2011; 
Matsumoto, Horie, Takayama, et al., 2005; Takayama, 2004). Mitragynine has been 
found to exhibit antinociceptive and analgesic effects in animal models (Matsumoto et 
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al., 2005; Takayama et al., 2002; Takayama, 2004; Watanbe et al., 1997; Yamamoto et 
al., 1997). Additionally, long-term exposure to mitragynine has been shown to produce 
dependence and withdrawal symptoms similar to those of opioid withdrawal upon 
cessation, in animal models (Babu, McCurdy & Boyer, 2008; Matsumoto et al., 2005; 
Thongpradichote, Matsumoto, Tohda et al., 1998). Mitragynine also exhibits a high 
affinity for µ-opioid receptors (MORs), classifying it as a MOR agonist (Watanabe et al., 
1997; Yamamoto et al., 1999).  
 MORs are highly involved in analgesic and euphoric pathways as well as play a 
significant role in addiction (Contet et al., 2004; McDonald & Lambert, 2005; Watanabe 
et al., 1997; Yamamoto et al., 1999). Considering their role in addiction, it is not 
surprising that MORs are largely located along reward pathways in the brain. MORs 
mediate the reinforcing activity of morphine and other opioids and are also thought to 
play a role in the continuance of drug use, cravings, and relapse (Gerrits, Lesscher & van 
Ree, 2003). Commonly used opioids that act on MORs include morphine, codeine, 
hydrocodone, heroine, and cocaine (European College of Neuropsychopharmacology, 
2007; Contet, Kieffer & Befort, 2004; Trescot, Datta, Lee & Hansen, 2008).  
  Although M. speciosa has been outlawed in Thailand since 1943, and several 
other East Asian countries, it has not yet been banned in the United States (Siebert, 2006; 
Vitayanartpaisarn et al., 2005). However, according to the U.S. Drug Enforcement 
Administration (2006) the increasing use and availability of M. speciosa is concerning. 
Over the past 15 years, M. speciosa has become increasingly used and widely available in 
“smoke” or “head” shops as well as over the Internet (US Drug Enforcement 
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Administration [DEA], 2006; Krauth, 2011; Osterhaus, 2008; Schmidt, Sharma, Schifano 
& Feinmann, 2011; Adkins et al., 2011) In fact, M. speciosa products in the form of 
tablets, capsules, concentrated extracts, and dried leaves are easily obtained from 
suppliers via the Internet (Krauth, 2011; Osterhaus, 2008).  
 Sufka et al. (2014) sought to determine if M. speciosa or its major constituents 
have an abuse liability. Rats were exposed to conditioned place preference, a behavioral 
assay, in which either test compounds or saline were administered via intraperitoneal (IP) 
injections on alternating days in two distinctly different chambers (Sufka et al., 2014). 
These researchers found mitragynine and M. speciosa extract, to a lesser extent, produce 
a place preference comparable to amphetamine. These findings suggest that M. speciosa 
has a high abuse potential (Sufka et al., 2014).  
 Given that mitragynine exhibits a high affinity for MORs, it seems necessary to 
compare M. speciosa to other known and abused MOR agonists, morphine and 
oxycodone (Koob, Sanna & Bloom, 1998; Lemberg et al., 2006; Matsumoto et al., 1996; 
Watanabe et al., 1997; Wood and Iyengar, 1988; Yamamoto et al., 1999). A considerable 
amount of literature is available on the abuse liabilities of morphine and oxycodone 
(Bannon & Malmberg, 2007; Contet et al., 2004). The standard assay for measuring 
MOR agonist activity on antinociception is the hotplate test (Bannon & Malmberg, 
2007). Similar hotplate response latencies between M. speciosa and the two well-known 
opioids, morphine and oxycodone, will suggest a high abuse potential for the under-
researched botanical. The purpose of this research is 1) to investigate M. speciosa and its 
components for activity similar to other well-known and commonly abused opioids, 
 5 
morphine and oxycodone 2) to see if this activity is still exhibited when the botanical 
compound or its components are administered orally and 3) after oral administration at 
what time points (30 or 60 minutes) during testing are drug effects apparent. These 
objectives will be addressed in two separate experiments. 
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Materials and methods 
Subjects 
Male Sprague Dawley rats (175-200 g, 6-7 weeks old; Harlan, Indianapolis, IN) were 
housed in pairs and maintained under a 12-hour light/dark cycle in a temperature and 
humidity controlled vivarium. Food and water were available ad libitum. In experiment 1, 
60 animals were handled daily 5 days prior to testing in order to minimize any 
experimenter-related stress. In experiment 2, 40 naive animals were handled and trained 
to drink a small amount of sucrose water (.2 ml) via a gavage-type feeding tube twice 
daily for a period of 5 days. Such training was performed in order to acclimate animals to 
the gavage procedure for oral route of administration and reduce experimenter-related 
stress. 
 
Drugs 
In Experiment 1, rats were given vehicle, 10 mg/kg morphine, 3 mg/kg oxycodone, 300 
mg/kg M. speciosa extract, 75 mg/kg M. speciosa fraction, or 30 mg/kg mitragynine IP 
30 minutes prior to hotplate testing. In experiment 2, rats were given, via oral gavage, 
vehicle, 6 mg/kg oxycodone, 300 mg/kg M. speciosa extract, or 100 mg/kg mitragynine. 
During gavage administration, the rat was restrained in the upright position while a 
stainless steel feeding tube was inserted into the stomach to deliver the test compounds. 
Hotplate tests were conducted at 30 and 60 minutes post drug administration. 
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Hotplate 
The hotplate test was utilized to characterize analgesic properties of test compounds 
against thermal nociception. For testing, animals were placed into an acrylic enclosure 
positioned on top of a hotplate maintained at 52 °C (Harvard Apparatus, Model # 52-
8570). Latency to flutter or lick a hindpaw or perform an escape response (i.e. jumping 
out of the apparatus) was recorded.  A 45 second cut-off score was employed for testing. 
All animals were returned to their home cages upon completion of testing (and in 
between tests in Experiment 2).
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Results 
Experiment 1 
The effects of test articles on hotplate response latencies are presented in Fig. 1.  
Compared to the vehicle group, the reference groups, morphine and oxycodone, had 
longer hotplate response latencies. The M. speciosa extract and fraction failed to show 
any antinociceptive effect, but mitragynine exhibited a longer hotplate response latency 
compared to the vehicle group. A one-way ANOVA revealed a significant main effect for 
treatment condition F(5,53)=6.734, p < 0.0001. Post-hoc analyses revealed that the mean 
hotplate response latency for morphine (p=0.0001) and oxycodone (p=0.039) were 
significantly longer than the vehicle. Mitragynine also showed a mean hotplate latency 
(p=0.022) significantly longer than the vehicle. All other relevant comparisons were not 
statistically significant. 
 
Experiment 2 
The effects of orally administered test compounds on hotplate response latencies are 
presented in Fig. 2. At 30 minutes post-administration, data trended towards but failed to 
reach significance. At 60 minutes post-administration, oxycodone, the reference group, 
had a longer hotplate response latency compared to the vehicle group. Mitragynine, but 
not M. speciosa, also exhibited a longer response latency as compared to the vehicle 
group. A one-way ANOVA revealed a significant main effect for treatment condition 
F(3,30)=2.093, p < 0.122. Post-hoc analyses revealed that the mean hotplate latency for 
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oxycodone (p=0.048) were significantly longer than the vehicle. Mitragynine also 
showed a mean hotplate latency (p=0.037) significantly longer than the vehicle. All other 
relevant comparisons were not statistically significant. 
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Discussion 
 The goal of this research was to compare the effects of M. speciosa and 
mitragynine against the effects of known, classic opioids, morphine and oxycodone. Our 
secondary goal was to determine if mitragynine and its parent compound produced 
similar effects when administered orally as when administered IP. Typically, the 
temporal dynamics of orally administered compounds differ from those administered IP, 
and consequently we sought to determine their time point of action (30 or 60 minutes). In 
our assays, the reference compounds, morphine and oxycodone, illustrated 
antinociceptive effects on the hotplate test regardless of administration route. These 
results are consistent with the extensive research exhibited in numerous models of the 
role of morphine and oxycodone, MOR agonists, in analgesia (Koob, Sanna & Bloom, 
1998; Lemberg et al., 2006; Wood and Iyengar, 1988). 
 As expected, mitragynine showed analgesic effects similar to oxycodone when 
administered IP. M. speciosa trended towards but failed to reach significance. This 
pattern of effect was also exhibited by mitragynine when administered orally. Again, M. 
speciosa trended towards but failed to reach significance when orally administered. 
Given that mitragynine is a MOR agonist it is not surprising that it exhibits analgesic 
effects on the hotplate (Watanabe et al., 1997; Yamamoto et al., 1999). These results are 
consistent with Macko et al. (1972), Sabetghadam, Ramanathan, and Mansor (2010), and 
Takayama, Ishikawa, Kurihara (2002) who found analgesic effects on the hotplate in 
rodent models.  
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There are many major concerns with the botanical M. speciosa. First, M. speciosa has 
become increasingly used by and widely available to consumers in the United States 
(DEA, 2006; Krauth, 2011; Schmidt et al., 2011; Adkins et al., 2011). Additionally, 
mitragynine, the active component in M. speciosa, is a MOR agonist like other known 
and commonly abused opioids, morphine and oxycodone (Adkins et al., 2011; 
Matsumoto et al., 2005; Takayama, 2004; Watanabe et al., 1997; Yamamoto et al., 
1999). MORs play a substantial role in addiction as well as analgesic and euphoric 
pathways (Contet et al., 2004; McDonald & Lambert, 2005; Watanbe et al., 1997; 
Yamamoto et al., 1999). Furthermore, Sufka et al., (2014) found that mitragynine and its 
parent compound, M. speciosa, exhibit an abuse liability comparable to that of 
amphetamine. In fact, mitragynine and its parent compound exhibit analgesic effects 
similar to oxycodone on the hotplate. Finally, mitragynine illustrates these effects even 
when orally consumed. The concerns outlined above illustrate the danger in consuming 
M. speciosa, albeit the need for higher doses and the longer period of activation. Further 
restrictions need to be placed on this dangerous botanical in the consumer marketplace. 
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Fig. 1. Hotplate Response Latencies at 30 Min Post IP Administration. The effects of 
M. speciosa extract, fraction, and active component, mitragynine, compared against 
morphine and oxycodone on the hotplate test. All drugs were administered IP. Morphine 
and oxycodone served as the control and were tested at 10 mg/kg and 3 mg/kg, 
respectively. The extract, fraction, and active component, mitragynine, were tested at 300 
mg/kg, 75 mg/kg, and 30 mg/kg, respectively.  Values represent mean latency to flutter, 
lick hindpaw, or attempt escape from the apparatus. * indicates a significant difference 
from the vehicle group. Sample sizes were n=10.
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Fig. 2. Hotplate Response Latencies at 30 Min Post Oral Administration. The effects 
of M. speciosa extract and active component, mitragynine, compared against oxycodone 
on the hotplate test at 30 minutes. All drugs were administered orally. Oxycodone served 
as the control and was tested at 6 mg/kg. The extract and active component, mitragynine, 
were tested at 300 mg/kg and 100 mg/kg, respectively. Values represent mean latency to 
flutter, lick hindpaw, or attempt escape from the apparatus. * indicates a significant 
difference from the vehicle group. Sample sizes were n=(8-10).  
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Fig. 3. Hotplate Response Latencies at 60 Min Post Oral Administration. The effects 
of M. speciosa extract and active component, mitragynine, compared against oxycodone 
on the hotplate test at 60 minutes. All drugs were administered orally. Oxycodone served 
as the control and was tested at 6 mg/kg. The extract and active component, mitragynine, 
were tested at 300 mg/kg and 100 mg/kg, respectively. Values represent mean latency to 
flutter, lick hindpaw, or attempt escape from the apparatus. * indicates a significant 
difference from the vehicle group. Sample sizes were n=(8-10).  
 
 
